European CHMP issues positive opinion recommending approval of license extension for Soliris (eculizumab)

Source:
European Medicines Agency - EMA
Publisher:
European Medicines Agency
Publication date:
26 July 2019

Abstract

CHMP has recommended approval of eculizumab for neuromyelitis optica spectrum disorder (NMOSD) in adults who are anti-aquaporin-4 (AQP4) antibody-positive with a relapsing course of the disease.